Diaceutics Launches Labceutics Laboratory Network in Europe in Support of Growing Personalized Medicine Market
Complete the form below to unlock access to ALL audio articles.
Diaceutics has announced the launch of Labceutics, a new laboratory network to service the growing personalized medicine (PM) market in Europe. Labceutics will focus on helping pharmaceutical companies and their diagnostic partners gain easier, more cost effective access to high quality test results for physicians and patients.
"The European laboratory market is fragmented with over 11,000 laboratories - from large public reference laboratories to small niche specialist labs," said Peter Keeling, chief executive officer of Diaceutics.
Keeling continued, "Labceutics helps pharma teams navigate this fragmented market to gain easy access to PM-ready labs that ensure efficient development and seamless access to companion diagnostic tests."
Labceutics will support pharmaceutical companies and diagnostic firms in support of Europe's growing PM market, a need that was recently underscored in a report by Frost & Sullivan (http://bit.ly/oxgLMF): "Pharmaceutical companies and diagnostic firms need to collaborate more closely with physicians during the theranostic development process, so that when the test is on the market, the endorsement of fellow physicians will aid in its greater adoption."
"The partnerships we've developed with over 80 high performance laboratories has resulted in Europe's broadest, partnership network of advanced one-stop shops for pharma's companion diagnostic needs," said Maria Fe Paz, managing director of Labceutics.
"Our sophisticated IT-enabled network can shave months off the normal lag time for introducing a novel diagnostic test into the market, and that should double the number of patients gaining access to new therapies," said Fe Paz.
"Laboratories are often the forgotten partner in companion diagnostics," said Dr. Miguel Martin, chief of medical oncology at Hospital General Universitario Gregorio Marañon in Madrid.
Dr. Martin continued, "As pharmaceutical companies assume greater responsibility for the integration of tests with their therapies, laboratories will play a critical role. Labceutics' partnerships will have tremendous benefits for physicians, clinical research programs, and most of all, patients."
